Advertisement

Topics

Wird AbbVie den Ausblick von Gilead Sciences kaputt machen?

02:31 EDT 7 Aug 2017 | FinanzNachrichten

Nachdem letzten Monat der Gesamtjahresausblick für die Hepatitis-C-Umsätze erhöht wurde, steigt die Aktie von Gilead Sciences (WKN:885823). Die FDA ließ letzte Woche aber das Hep-C-Medikament der n...

Original Article: Wird AbbVie den Ausblick von Gilead Sciences kaputt machen?

NEXT ARTICLE

More From BioPortfolio on "Wird AbbVie den Ausblick von Gilead Sciences kaputt machen?"

Quick Search
Advertisement
 

Relevant Topics

Hepatitis
Hepatitis (plural hepatitides) is a medical condition defined by the inflammation of the liver and characterized by the presence of inflammatory cells in the tissue of the organ. The condition can be self-limiting (healing on its own) or can progress to ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...